The Profectus Approach to Product Development and Commercialization

The Company has assembled a portfolio of innovative and synergistic technologies that are applicable to the development of prophylactic and therapeutic products to reduce the morbidity and mortality caused by viral diseases in humans and animals. Profectus is developing:

• Antiviral Immune Modulating (AIM) therapy: Profectus has developed a breakthrough antiviral therapy that combines specific immune modulating drugs with antiviral agents to solve the challenges faced by today’s anti-retroviral therapies.

• Transition-State Vaccines (TSV): Profectus has developed a platform technology group that targets the “Achilles heel” of highly variable enveloped viruses such as HIV to solve the problems with today’s vaccines such as mutations, short-term immunity and inability to distribute world-wide.